Wednesday, July 8, 2026

Patent intelligence · US

US 11208432

Inhibitors of glucocorticoid receptor

granted A61KA61K31/575A61K31/58A61K45/06
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 15
Applicant portfolio 52
Patent details — US 11208432
Jurisdiction
US
Status
granted
Grant date
Dec 28, 2021
Expiration
Dec 23, 2041
Claims
35
CPC classes
A61K, A61K31/575, A61K31/58, A61K45/06
View on Google Patents ↗

Quick answer

US 11208432 (Inhibitors of glucocorticoid receptor) is held by ORIC PHARMACEUTICALS, INC.. Status: granted. Granted Dec 28, 2021. Expires Dec 23, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
35
CPC classes
A61K, A61K31/575, A61K31/58, A61K45/06, A61P, A61P35/00

More from ORIC PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12312339

    Polo like kinase 4 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires May 22, 2045

    granted
  2. US 12239729

    TRPV3 agonists for the treatment of skin conditions

    Soricimed Biopharma Inc. · Expires Feb 27, 2045

    granted
  3. US 12054556

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Expires Aug 1, 2044

    granted
  4. US 12018043

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires Jun 20, 2044

    granted
  5. US 12005080

    Method for promoting proliferation of immune cells

    Oricell Therapeutics Co., Ltd. · Expires Jun 6, 2044

    granted
  6. US 11993655

    Anti-PD-L1 antibody and use thereof

    Oricell Therapeutics Co., Ltd. · Expires May 23, 2044

    granted
  7. US 11858915

    Polo like kinase 4 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires Dec 28, 2043

    granted
  8. US 11807658

    CD73 inhibitors

    ORIC PHARMACEUTICALS, INC. · Expires Nov 2, 2043

    granted

Frequently asked questions

What is US patent 11208432?

US 11208432 (Inhibitors of glucocorticoid receptor) is held by ORIC PHARMACEUTICALS, INC.. Status: granted. Granted Dec 28, 2021. Expires Dec 23, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11208432?

ORIC PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.

When does US 11208432 expire?

Our index shows an expiration date of Dec 23, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.